A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia

Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) with in vitro pro-apoptotic and antiangiogenic effects on chronic lymphocytic leukemia (CLL) cells. As monotherapy in patients with CLL, it has no clinical activity. Here we report the results of an open-label,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Kay, Neil E., Strati, Paolo, LaPlant, Betsy R., Leis, Jose F., Nikcevich, Daniel, Call, Timothy G., Pettinger, Adam M., Lesnick, Connie E., Hanson, Curtis A., Shanafelt, Tait D.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Priority Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346637/
https://ncbi.nlm.nih.gov/pubmed/27861157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13412
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars